Fig 1: Single protein-injection of CALU or SOD1 improved glucose control. (A) Nonfasting plasma glucose levels measured from days 0-42 in mice iPan-injected with basal media (vehicle control, n = 7), 8-protein combination (n = 7), or each of the eight proteins individually (CALU, n = 6; SOD1, n = 6; CTSB, n = 7; FAM3C, n = 6; GAL1, n = 7; PSAP, n = 6; TGM2, n = 8; and PPIA, n = 6). (B) Area under the curve for plasma glucose (AUC P.G.) was reduced in mice iPan-injected with 8-protein combination, CALU, and SOD1. (C) Fasting plasma glucose was measured for 120 min following intraperitoneal injection of a glucose bolus and (D) area under the curve for fasting plasma glucose during the glucose tolerance test was lower in mice that were iPan-injected with 8-protein combination, CALU, SOD1, or CTSB, compared to basal media-injected controls. (E) Islet size was increased in mice iPan-injected with 8-protien combination and SOD1, while (F) beta cell mass was increased in mice iPan-injected with 8-protein combination, compared to basal media-injected controls. Dashed line represents data obtained from healthy controls (n = 6). Data represent mean ± SEM. Glucose data was compared using two-way ANOVA followed by Dunnett’s multiple comparisons test. AUC was compared using one-way ANOVA followed by Dunnett’s multiple comparison test (*P < 0.05, **P < .01 vs basal media).